Fireside chat: Across the finish line: What FDA BLA reviews really test and where European CGT teams are most often surprised

Submission-ready’ is not ‘FDA-ready’: What the FDA expects to see in a BLA beyond what typically satisfies EMA or national authorities and where European teams most often underestimate depth across CMC, clinical consistency and commercial readiness.

Evidence expectations don’t always translate: How European trial designs (adaptive approaches, investigator-led data, smaller populations) are interpreted by the FDA and where additional robustness, comparability or contextualisation is required.

Manufacturing confidence under the FDA lens: How the FDA assesses process control, validation maturity and comparability differently from European regulators—and why distributed manufacturing and evolving processes raise questions earlier than EU teams expect.

Interpreting FDA feedback in practice: How to read between the lines of FDA questions, information requests and timelines and how experienced teams adjusted strategy, data presentation or sequencing in response.

Approval is not just clinical: How commercial readiness, post-approval commitments and lifecycle planning influence FDA confidence and what European teams often leave too late when preparing for BLA revi